USE OF HIGH DOSE RIFAMPICIN FOR THE TREATMENT OF TUBERCULOSIS MENINGITIS PATIENTS: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.53555/nnmhs.v9i2.1557Keywords:
High-dose rifampicin, treatment, tuberculosis meningitisAbstract
Aim: The objective of this study is to summarize and evaluate the use of high-dose rifampicin for the treatment of tuberculosis meningitis.
Methods: A systematic search strategy was conducted across several electronic reference databases (PubMed, Cochrane Library, Google Scholar) and included articles published between 2018–2023. Duplicate publications, review articles, and incomplete articles were excluded.
Results: Database searches identified a total of 93 articles. Of these, 22 articles passed the screening process and resulted in 12 articles for full-text assessment. The 6 articles did not evaluate the outcome of interest. Hence, we found 6 appropriate studies included in this review.
Conclusion: The results suggest that high-dose rifampicin is not associated with the outcomes of tuberculosis meningitis patients. However, further research especially RCTs is recommended to evaluate comprehensive rifampicin regimens for the optimization of tuberculosis meningitis patients.
References
Rodriguez-Takeuchi SY, Renjifo ME, Medina FJ. Extrapulmonary tuberculosis: Pathophysiology and imaging findings. Radiographics. 2019 Nov 1;39(7):2023–37.
Arshad A, Dayal S, Gadhe R, Mawley A, Shin K, Tellez D, et al. Analysis of tuberculosis meningitis pathogenesis, diagnosis, and treatment. Vol. 9, Journal of Clinical Medicine. MDPI; 2020. p. 1–19.
Davis A, Meintjes G, Wilkinson RJ. Treatment of Tuberculous Meningitis and Its Complications in Adults. Vol. 20, Current Treatment Options in Neurology. Current Science Inc.; 2018.
Snow KJ, Cruz AT, Seddon JA, Ferrand RA, Chiang SS, Hughes JA, et al. Adolescent tuberculosis. Vol. 4, The Lancet Child and Adolescent Health. Elsevier B.V.; 2020. p. 68–79.
Furin J, Cox H, Pai M. Tuberculosis. Vol. 393, The Lancet. Lancet Publishing Group; 2019. p. 1642–56.
Manyelo CM, Solomons RS, Walzl G, Chegou NN. Tuberculous meningitis: Pathogenesis, immune responses, diagnostic challenges, and the potential of biomarker-based approaches. Vol. 59, Journal of Clinical Microbiology. American Society for Microbiology; 2021.
Donovan J, Thwaites GE, Huynh J. Tuberculous meningitis: Where to from here? Vol. 33, Current Opinion in Infectious Diseases. Lippincott Williams and Wilkins; 2020. p. 259–66.
Davis AG, Rohlwink UK, Proust A, Figaji AA, Wilkinson RJ. The pathogenesis of tuberculous meningitis. Vol. 105, Journal of Leukocyte Biology. John Wiley and Sons Inc; 2019. p. 267–80.
Zaw MT, Emran NA, Lin Z. Mutations inside rifampicin-resistance determining region of rpoB gene associated with rifampicin-resistance in Mycobacterium tuberculosis. Vol. 11, Journal of Infection and Public Health. Elsevier Ltd; 2018. p. 605–10.
Seijger C, Hoefsloot W, Guchteneire IB de, te Brake L, van Ingen J, Kuipers S, et al. High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre. PLoS One. 2019 Mar 1;14(3).
Cresswell F v., Musubire AK, Johansson Århem KM. Treatment guidelines for tuberculosis and tuberculous meningitis. In: Tuberculous Meningitis. Elsevier; 2020. p. 67–101.
Abulfathi AA, Decloedt EH, Svensson EM, Diacon AH, Donald P, Reuter H. Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis. Vol. 58, Clinical Pharmacokinetics. Springer International Publishing; 2019. p. 1103–29.
Dian S, Yunivita V, Ganiem AR, Pramaesya T, Chaidir L, Wahyudi K, et al. Double-Blind, Randomized, Placebo-Controlled Phase II Dose-Finding Study To Evaluate High-Dose Rifampin for Tuberculous Meningitis. 2018; Available from: https://doi.org/10.1128/AAC
Ding J, Thuy Thuong Thuong N, Pham T van, Heemskerk D, Pouplin T, Tran CTH, et al. Pharmacokinetics and Pharmacodynamics of Intensive Antituberculosis Treatment of Tuberculous Meningitis. Clin Pharmacol Ther. 2020 Apr 1;107(4):1023–33.
Wasserman S, Davis A, Stek C, Chirehwa M, Botha S, Daroowala R, et al. Plasma Pharmacokinetics of High-Dose Oral versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized Controlled Trial. 2021; Available from: https://doi.org/10.1128/AAC
Paradkar MS, Devaleenal D B, Mvalo T, Arenivas A, Thakur KT, Wolf L, et al. Randomized Clinical Trial of High-Dose Rifampicin With or Without Levofloxacin Versus Standard of Care for Pediatric Tuberculous Meningitis: The TBM-KIDS Trial. Clin Infect Dis. 2022 Oct 29;75(9):1594–601.
Cresswell F v., Meya DB, Kagimu E, Grint D, te Brake L, Kasibante J, et al. High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial. Clinical Infectious Diseases. 2021 Sep 1;73(5):876–84.
Garcia-Prats AJ, Svensson EM, Winckler J, Draper HR, Fairlie L, van der Laan LE, et al. Pharmacokinetics and safety of high-dose rifampicin in children with TB: The Opti-Rif trial. Journal of Antimicrobial Chemotherapy. 2021 Dec 1;76(12):3237–46.
Espinosa-Pereiro J, Ghimire S, Sturkenboom MGG, Alffenaar JWC, Tavares M, Aguirre S, et al. Safety of Rifampicin at High Dose for Difficult-to-Treat Tuberculosis: Protocol for RIAlta Phase 2b/c Trial. Pharmaceutics. 2022 Dec 20;15(1):9.
Espinosa-Pereiro J, Sánchez-Montalvá A, Aznar ML, Espiau M. MDR Tuberculosis Treatment. Vol. 58, Medicina (Lithuania). MDPI; 2022.
Peloquin CA, Davies GR. The Treatment of Tuberculosis. Clin Pharmacol Ther. 2021 Dec 1;110(6):1455–66.
Malenfant JH, Brewer TF. Rifampicin Mono-Resistant Tuberculosis - A Review of an Uncommon but Growing Challenge for Global Tuberculosis Control. Vol. 8, Open Forum Infectious Diseases. Oxford University Press; 2021.
Atwine D, Baudin E, Gelé T, Muyindike W, Mworozi K, Kyohairwe R, et al. Effect of high-dose rifampicin on efavirenz pharmacokinetics: Drug-drug interaction randomized trial. Journal of Antimicrobial Chemotherapy. 2020 May 1;75(5):1250–8.
Howard NC, Khader SA. Immunometabolism during Mycobacterium tuberculosis Infection. Vol. 28, Trends in Microbiology. Elsevier Ltd; 2020. p. 832–50.
Marais S, Cresswell F v, Hamers RL, te Brake LHM, Ganiem AR, Imran D, et al. High dose oral rifampicin to improve survival from adult tuberculous meningitis: A randomised placebo-controlled double-blinded phase III trial (the HARVEST study). Wellcome Open Res. 2019 Dec 2;4:190.
Ruiz-Bedoya CA, Mota F, Tucker EW, Mahmud FJ, Reyes-Mantilla MI, Erice C, et al. High-dose rifampin improves bactericidal activity without increased intracerebral inflammation in animal models of tuberculous meningitis. Journal of Clinical Investigation. 2022 Mar 15;132(6).
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Journal of Advance Research in Medical & Health Science
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
